In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Menveo Market Performed in Recent Years, and What Does Its Future Hold? The Menveo market has experienced ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another $430 million. Pfizer has been something of an also-ran in the ...